WASHINGTON / RankWire.AI / – The Dana-Farber Cancer Institute, in collaboration with the 23andMe Research Institute, has reported the discovery of a rare inherited genetic mutation that significantly elevates lung cancer risk. According to groundbreaking research published in the journal Science, this mutation increases the likelihood of developing lung cancer roughly 25 times overall and as much as 60 times in individuals who have never smoked. The study analyzed de-identified genetic data from over 3.3 million individuals. The researchers identified the germline variant, known as EGFR T790M, as one of the most potent inherited risk factors for lung cancer identified to date.
This mutation is found in the epidermal growth factor receptor gene, which plays a critical role in controlling cell growth and division within lung tissue. While somatic EGFR mutations, which are acquired during a person’s lifetime, are recognized drivers of non-small cell lung cancer, the T790M germline variant is inherited from birth and present in all cells. Data from the National Cancer Institute indicates that approximately 1 in every 15,850 people in the United States carries this mutation. Dr. Jaclyn LoPiccolo, the lead author of the study, pointed out that carrying this genetic variant increases lung cancer risk by about 62 times in never-smokers, compared to roughly 11 times among those with a history of smoking.
Genealogy analysis revealed that the EGFR T790M variant is disproportionately concentrated among populations in Southern Appalachia, specifically across Tennessee and Alabama. Evolutionary geneticists determined that the mutation originated among British and Irish settlers who migrated to North America during colonial times, with its prevalence increasing after a genetic bottleneck approximately 200 years ago. Senior author Dr. Pasi A. Jänne emphasized that, although current lung cancer screening mainly focuses on tobacco exposure, identifying potent genetic risk factors could lead to targeted screening approaches, such as low-dose computed tomography, for non-smoking carriers.
Mutation May Elevate Lung Cancer Risk by Up to 60 Times in Non-Smokers
Supported by the National Institutes of Health, both preclinical and clinical studies confirmed that this specific mutation has a strong association with lung cancer, showing no significant links to 17 other common cancers evaluated in the dataset. Oncologists acknowledge that although tobacco remains the primary cause of lung cancer overall, the increasing incidence among non-smokers has become a major global health concern. Pharmaceutical companies, including AstraZeneca, continue developing targeted therapies like Tagrisso, a tyrosine kinase inhibitor, to treat EGFR-mutated lung tumors when they progress.
Co-lead researcher Dr. Alexander Gusev observed that this study highlights how a single inherited point mutation can have an extraordinarily strong influence on disease risk. Medical experts advise that individuals with multiple family members affected by lung cancer, unexplained multifocal lung nodules, or ancestral ties to Southern Appalachia should seek genetic counseling. The researchers underline that possessing the mutation does not guarantee lung cancer development; environmental factors and other genetic modifications also play critical roles in whether malignant transformation occurs during a person’s lifetime.
Multi-Center Study Analyzes Genetic Data from Over Three Million Participants
The research consortium intends to expand its observational efforts through the ongoing INHERIT Study, aiming to evaluate additional inherited EGFR variants across diverse racial groups. Long-term monitoring will seek to identify environmental triggers and secondary genomic changes that determine why some carriers develop tumors while others remain unaffected.
Comprehensive details on population genetics, relative risk assessments, and screening guidelines are accessible through peer-reviewed medical archives and institutional release portals. Future updates on biomarker data will be presented at upcoming international oncology conferences to inform new screening protocols.